The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support

Anja Irmisch, Ximena Bonilla, Stéphane Chevrier, Kjong-Van Lehmann, Franziska Singer, Nora C. Toussaint, Cinzia Esposito, Julien Mena, Emanuela S. Milani, Ruben Casanova, Daniel J. Stekhoven, Rebekka Wegmann, Francis Jacob, Bettina Sobottka, Sandra Goetze, Jack Kuipers, Jacobo Sarabia del Castillo, Michael Prummer, Anıl Tuncel, Ulrike Menzel, Alice K. Jacobs, Stefanie Engler, Sujana Sivapatham, Anja Frei, Gabriele Gut, Joanna Ficek, Reinhard Dummer, Ruedi Aebersold, Marina Bacac, Niko Beerenwinkel, Christian Beisel, Bernd Bodenmiller, Viktor H. Koelzer, Holger Moch, Lucas Pelkmans, Berend Snijder, Markus Tolnay, Bernd Wollscheid, Gunnar Rätsch, Mitchell P. LevesquemedRxiv 2020 · DOI

Abstract

Recent technological advances allow profiling of tumor samples to an unparalleled level with respect to molecular and spatial composition as well as treatment response. We describe a prospective, observational clinical study performed within the Tumor Profiler (TuPro) Consortium that aims to show the extent to which such comprehensive information leads to advanced mechanistic insights of a patient’s tumor, enables prognostic and predictive biomarker discovery, and has the potential to support clinical decision making. For this study of melanoma, ovarian carcinoma, and acute myeloid leukemia tumors, in addition to the emerging standard diagnostic approaches of targeted NGS panel sequencing and digital pathology, we perform extensive characterization using the following exploratory technologies: single-cell genomics and transcriptomics, proteotyping, CyTOF, imaging CyTOF, pharmacoscopy, and 4i drug response profiling (4i DRP). In this work, we outline the aims of the TuPro study and present preliminary results on the feasibility of using these technologies in clinical practice showcasing the power of an integrative multi-modal and functional approach for understanding a tumor’s underlying biology and for clinical decision support.

Introduction: Beyond Genomic Matching

Current precision oncology relies heavily on Next-Generation Sequencing (NGS) of bulk tumor tissue. While identifying genetic mutations is valuable, it often fails to account for the complex tumor microenvironment, cellular heterogeneity, or the actual functional state of the cancer cells. Statistics suggest that only about one-third of patients treated based on NGS-matched therapies achieve a significant clinical response.

The Tumor Profiler (TuPro) study addresses this limitation by asking whether integrating a broader suite of exploratory technologies—including single-cell analysis, proteomics, and ex vivo drug testing—can provide a more accurate map of tumor biology and lead to more effective treatment recommendations. A critical component of this study is testing the feasibility of generating such complex data within a timeframe that allows for real-world clinical intervention.

Study Design and Workflow

The TuPro study is structured around two distinct research and development loops. The Fast Diagnostics Loop is designed to process patient samples and return a molecular summary report within a two-week window, supporting the Tumor Board's treatment decisions. Parallel to this, the Exploratory Science Loop utilizes the same data for long-term hypothesis generation and biomarker discovery across the full patient cohort.

Figure 1: Overview of the Tumor Profiler study design, timeline, and multi-omic workflow. (A) The dual-loop R&D approach. (B) Study timeline for different cancer indications. (C) Detailed pipeline from sample collection to clinical decision support.

The workflow integrates two standard diagnostic methods with six exploratory technologies:

  • Standard Diagnostics: Targeted NGS and Digital Pathology.
  • Single-Cell Analysis: scRNA-seq and scDNA-seq to map cellular heterogeneity and evolutionary lineages.
  • Proteotyping: Mass spectrometry-based quantification of thousands of proteins to assess the tumor's active machinery.
  • CyTOF & Imaging Mass Cytometry (IMC): High-dimensional single-cell protein analysis in suspension and within the spatial context of the tissue.
  • Functional Profiling: Pharmacoscopy and 4i drug response profiling (4i DRP) involve exposing live tumor cells to drug libraries ex vivo to measure direct sensitivity.

Key Insights and Clinical Feasibility

Preliminary results from the TuPro consortium highlight several critical findings:

1. Multi-Modal Convergence

The study found high consistency across diverse technologies. For example, cell-type fractions reported by CyTOF (protein-based) and scRNA-seq (RNA-based) were highly concordant, validating the robustness of the multi-omic approach.

2. Functional vs. Genomic Disconnect

The data revealed that genetic mutations do not always translate to active signaling pathways. In specific cases, while NGS suggested a particular inhibitor, functional drug testing and single-cell signaling analysis showed the pathway was not the primary driver, potentially preventing the administration of ineffective treatments.

3. Spatial Context

Using IMC, researchers identified spatial "handshakes" between PD-1 positive T-cells and PD-L1 positive tumor cells. This spatial proximity is a more potent predictor of immunotherapy response than bulk protein levels alone.

4. Clinical Turnaround and Actionability

Crucially, the study demonstrated that this high-tech pipeline can achieve a two-week turnaround time for the molecular summary report. A notable case study (Patient TP-M2-USZ-010) illustrated the power of this approach: while standard NGS provided only low-confidence options, the TuPro pipeline identified a low-level copy number gain in CDK4 and confirmed high CDK4 protein expression. Functional testing subsequently showed high sensitivity to CDK4/6 inhibitors, providing a clear, evidence-based treatment path that genomic sequencing alone missed.

Conclusion and Future Directions

The TuPro study establishes a framework for the next generation of precision oncology. By moving from "genomic matching" to "functional profiling," clinicians can gain a deeper understanding of a patient's unique tumor biology. While currently observational, the study's success in feasibility and data integration sets the stage for future interventional trials where multi-omic data directly guides treatment selection. Future efforts will focus on scaling the cohort to 240 patients and adapting clinical ranking scales to incorporate proteomic and functional evidence.

Summary updated

Abstract

Abstract Recent technological advances allow profiling of tumor samples to an unparalleled level with respect to molecular and spatial composition as well as treatment response. We describe a prospective, observational clinical study performed within the Tumor Profiler (TuPro) Consortium that aims to show the extent to which such comprehensive information leads to advanced mechanistic insights of a patient’s tumor, enables prognostic and predictive biomarker discovery, and has the potential to support clinical decision making. For this study of melanoma, ovarian carcinoma, and acute myeloid leukemia tumors, in addition to the emerging standard diagnostic approaches of targeted NGS panel sequencing and digital pathology, we perform extensive characterization using the following exploratory technologies: single-cell genomics and transcriptomics, proteotyping, CyTOF, imaging CyTOF, pharmacoscopy, and 4i drug response profiling (4i DRP). In this work, we outline the aims of the TuPro study and present preliminary results on the feasibility of using these technologies in clinical practice showcasing the power of an integrative multi-modal and functional approach for understanding a tumor’s underlying biology and for clinical decision support.
BibTeX
@misc{irmisch2020tumor,
  author = {Anja Irmisch and Ximena Bonilla and Stéphane Chevrier and Kjong-Van Lehmann and Franziska Singer and Nora C. Toussaint and Cinzia Esposito and Julien Mena and Emanuela S. Milani and Ruben Casanova and Daniel J. Stekhoven and Rebekka Wegmann and Francis Jacob and Bettina Sobottka and Sandra Goetze and Jack Kuipers and Jacobo Sarabia del Castillo and Michael Prummer and Anıl Tuncel and Ulrike Menzel and Alice K. Jacobs and Stefanie Engler and Sujana Sivapatham and Anja Frei and Gabriele Gut and Joanna Ficek and Reinhard Dummer and Ruedi Aebersold and Marina Bacac and Niko Beerenwinkel and Christian Beisel and Bernd Bodenmiller and Viktor H. Koelzer and Holger Moch and Lucas Pelkmans and Berend Snijder and Markus Tolnay and Bernd Wollscheid and Gunnar Rätsch and Mitchell P. Levesque},
  title = {{The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support}},
  year = {2020},
  doi = {10.1101/2020.02.13.20017921},
  howpublished = {medRxiv},
}
Figure